Search Results
Search for "Foscarnet" returned 10 results
Showing 1-10 out of 10
| DrugBank ID | Name | Formula | Weight |
|---|---|---|---|
DB00529
|
Foscarnet | CH3O5P | 126.0053 |
| The combination of foscarnet and ganciclovir has been shown to have enhanced activity in vitro. PA449706 14-17% 3415 595937 APRD00669 Carboxyphosphonic acid Dihydroxyphosphinecarboxylic acid oxide ... | |||
| DB01165
|
Ofloxacin | C18H20FN3O4 | 361.3675 |
| ... barbiturate Increased risk of cardiotoxicity and arrhythmias Foscarnet Increased risk of convulsions Iron Formation of non-absorbable complexes Magnesium Formation of non-absorbable complexes ... | |||
| DB01059
|
Norfloxacin | C16H18FN3O3 | 319.3308 |
| ... Dyphylline The quinolone increases the effect of theophylline Foscarnet Increased risk of convulsions Iron Formation of non-absorbable complexes Magnesium Formation of non-absorbable complexes ... | |||
| DB00537
|
Ciprofloxacin | C17H18FN3O3 | 331.3415 |
| ... effect of theophylline Ethotoin Decreases the hydantoin effect Foscarnet Increased risk of convulsions Fosphenytoin Decreases the hydantoin effect Iron Formation of non-absorbable complexes ... | |||
| DB01369
|
Quinupristin | C87H117N13O19S2 | 1713.0660 |
| ... This combination presents an increased risk of toxicity Foscarnet This combination presents an increased risk of toxicity Fosphenytoin This combination presents an increased risk of toxicity ... | |||
| DB00091
|
Cyclosporine | C62H111N11O12 | 1202.6112 |
| ... The protease inhibitor increases the effect of cyclosporine Foscarnet Monitor for nephrotoxicity Fosphenytoin The hydantoin decreases the effect of cyclosporine Glibenclamide The sulfonylurea ... | |||
| DB00539
|
Toremifene | C26H28ClNO | 405.9600 |
| Foscarnet Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co ... | |||
| DB01623
|
Thiothixene | C23H29N3O2S2 | 443.6250 |
| Foscarnet May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. | |||
| DB00864
|
Tacrolimus | C44H69NO12 | 804.0182 |
| Foscarnet Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. Gatifloxacin Additive QTc-prolongation may ... | |||
| DB00726
|
Trimipramine | C20H26N2 | 294.4338 |
| Foscarnet Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. Frovatriptan Increased risk of serotonin ... | |||
Showing 1-10 out of 10